HER2

SABCS 2025: Transforming HER2+ Breast Cancer Care: Key Updates from HER2CLIMB-05, DESTINY, and PHILA Trials

This article reviews recent pivotal HER2+ breast cancer trials, highlighting oral TKIs, antibody-drug conjugates, and chemotherapy-sparing strategies. Key studies—including HER2CLIMB-05, DESTINY-Breast11, DESTINY-Breast09, and PHILA—demonstrate improved...

Latest Post

TUKYSA Combination Improves Progression-Free Survival in First-Line HER2+ Metastatic Breast Cancer: HER2CLIMB-05 Phase 3 Results

TUKYSA combo improves PFS in first-line HER2+ metastatic breast cancer maintenance, the first update to...

Verzenio Demonstrates Overall Survival Benefit in High-Risk Early Breast Cancer: Seven-Year monarchE Results

Two years of Verzenio plus endocrine therapy shows OS benefit in high-risk HR+, HER2- early...

FDA Grants Priority Review to Enhertu Plus Pertuzumab for First-Line HER2+ Metastatic Breast Cancer

FDA grants Priority Review for Enhertu plus pertuzumab in first-line HER2+ metastatic breast cancer, with...

Verzenio Achieves Overall Survival Milestone in Early Breast Cancer Competition”

Verzenio plus endocrine therapy offers statistically significant OS improvements over endocrine therapy alone in high-risk...

Palbociclib Resistance Biomarkers in Advanced Breast Cancer

ctDNA genotyping reveals ESR1, PIK3CA mutations and CCND1, FGFR1 amplifications predict worse outcomes with palbociclib...

T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer

T-DXd plus pertuzumab nearly doubled progression-free survival compared to standard THP for first-line metastatic HER2+...

Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2– Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial

Dalpiciclib + ET significantly improved iDFS in HR+/HER2- early breast cancer: 24-month rates 94.7% vs...

Breast Cancer Insight Center

HR

Triple Negative Breast Cancer (TNBC)

About
Contact
Privacy Policy
Terms of Use

About
Contact
Privacy Policy
Terms of Use

732-455-2192
contact@oncologynexus.com

Facebook-f Twitter Google-plus-g Pinterest